ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,718.57
      0.28%
      US Tech 100
      19,312.80
      0.08%
      Dow Jones
      42,124.65
      0.15%
      Brent Oil
      74.105
      0.50%
      Bitcoin
      63,326.16
      0.00%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. F star Therapeutics Inc (FSTX) Quote

      F star Therapeutics Inc

      F star Therapeutics Inc (FSTX)

      NASDAQ
      7.12
      0.00
      (0.00%)
      Closed September 24 4:00PM
      Delayed by 15 minutes
      0.00
      0.00
      (0.00%)
      After Hours: -
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      7.12
      Bid
      7.20
      Ask
      7.72
      Volume
      -
      0.00 Day's Range 0.00
      7.12 52 Week Range 7.12
      Previous Close
      7.12
      Open
      -
      Last Trade
      Last Trade Time
      Average Volume (3m)
      -
      Financial Volume
      -
      VWAP
      -

      Ask ADVFN Intelligence (AI)

      FSTX Latest News

      More News

      F-star Announces Issuance of U.S. Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 and LAG-3

      Provides U.S. Patent Protection to at least August 2038 Expands Patent Protection for FS118 Composition of Matter beyond Europe CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2022...

      January 20 2022
      GlobeNewswire Inc.

      F-star Therapeutics to Participate in Upcoming Investor Conferences

      CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing...

      January 07 2022
      GlobeNewswire Inc.

      F-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology Collaboration

      CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing...

      January 05 2022
      GlobeNewswire Inc.

      F-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021

      CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 07, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing...

      December 07 2021
      GlobeNewswire Inc.

      F-star Therapeutics to Host Virtual R&D Day on December 6, 2021

      CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing...

      November 29 2021
      GlobeNewswire Inc.

      F-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 Conference

      Dr. Michelle Morrow to present on F-star’s Proprietary Bispecific Platform including FS118, our LAG-3/PD-L1 Bispecific Poster Presentation of Preclinical Data Demonstrates Potential for F-star’s...

      November 12 2021
      GlobeNewswire Inc.

      F-star Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

      Company to Host Conference Call Today at 9 a.m. EST CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) --  F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage...

      November 10 2021
      GlobeNewswire Inc.

      F-star Therapeutics to Announce Third Quarter Results and Host Conference Call on November 10, 2021

      CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing...

      November 01 2021
      GlobeNewswire Inc.

      F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics

      CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Ltd. (NASDAQ: FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company...

      October 20 2021
      GlobeNewswire Inc.

      F-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress Update at ESMO 2021

      CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing...

      September 16 2021
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1007.127.127.1200CS
      4007.127.127.1200CS
      12007.127.127.1200CS
      26007.127.127.1200CS
      52007.127.127.1200CS
      156-0.49-6.438896189227.618.362.071511425.55179314CS
      2603.2282.56410256413.915.52.071494126.10128151CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      KAVLKaival Brands Innovations Group Inc
      $ 1.33
      (129.71%)
      		182.46M
      LASELaser Photonics Corporation
      $ 18.8671
      (81.24%)
      		13.54M
      TGLTreasure Global Inc
      $ 1.18
      (73.45%)
      		139.95M
      NVVENuvve Holding Corporation
      $ 6.68
      (70.41%)
      		31.34M
      UXINUxin Ltd
      $ 2.42
      (52.68%)
      		18.24M
      ELABElevai Labs Inc
      $ 0.10545
      (-62.34%)
      		23.66M
      ADTXAditxt Inc
      $ 0.262
      (-31.52%)
      		3.17M
      FRGTFreight Technologies Inc
      $ 0.081
      (-28.82%)
      		26.36M
      ANEBAnebulo Pharmaceuticals Inc
      $ 2.23
      (-27.60%)
      		113.78k
      STSSSharps Technology Inc
      $ 0.1722
      (-27.06%)
      		2.28M
      XPONExpion360 Inc
      $ 0.1144
      (34.91%)
      		432.21M
      NVDANVIDIA Corporation
      $ 116.26
      (0.22%)
      		206.23M
      INTCIntel Corporation
      $ 22.56
      (3.30%)
      		184.44M
      KAVLKaival Brands Innovations Group Inc
      $ 1.33
      (129.71%)
      		182.46M
      TGLTreasure Global Inc
      $ 1.18
      (73.45%)
      		139.95M

      FSTX Discussion

      View Posts
      DK11 DK11 2 years ago
      https://www.sec.gov/Archives/edgar/data/1566373/000119312522309497/d427731dsc14d9a.htm
      And last one I hope. Lol....
      👍️0
      DK11 DK11 2 years ago
      https://www.sec.gov/Archives/edgar/data/1566373/000119312522309497/d427731dsc14d9a.htm
      Here is more information on this.
      👍️0
      DK11 DK11 2 years ago
      https://www.sec.gov/Archives/edgar/data/1566373/000119312522309500/d439272d8k.htm
      Looks like good news to me
      👍️0
      subslover subslover 2 years ago
      invoX Pharma to Acquire F-Star Therapeutics (FSTX) for $7.12 Per Share
      https://www.streetinsider.com/Corporate+News/invoX+Pharma+to+Acquire+F-Star+Therapeutics+%28FSTX%29+for+%247.12+Per+Share/20245945.html
      👍️0
      rhopton rhopton 3 years ago
      someone has been hitting the sell button for 5 days straight, this is getting ridiculous that it can't move on major news like that, but these other stocks move 2 to 3 hundred percent on nothing
      👍️0
      maximumgriff maximumgriff 3 years ago
      FJB!!!
      👍️0
      Docstemcell2020 Docstemcell2020 3 years ago
      Let's go Brandon! FJB
      👍️0
      maximumgriff maximumgriff 3 years ago
      Kinda crazy this hasn’t taken off with this mega license deal
      👍️0
      maximumgriff maximumgriff 3 years ago
      Big news
      👍️0
      crudeoil24 crudeoil24 3 years ago
      F-star Therapeutics Reports License Deal With J&J's Janssen To Develop, Commercialize Multiple Next Gen Bispecific Antibody Therapeutics; Co. To Receive Upfront Fees Of $17.5M, Near-Term Fees, Milestones Up To $1.35B
      8:04 am ET October 20, 2021 (Benzinga) Print
      F-star Therapeutics, Ltd. (NASDAQ:FSTX) (“F-star” or the “Company”), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of patients with cancer, today announced that it has entered into a license and collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by Johnson & Johnson Innovation.

      Under the terms of the agreement, F-star will grant Janssen a worldwide, exclusive royalty-bearing license to research, develop, and commercialize up to five novel bispecific antibodies directed to Janssen therapeutic targets using F-star’s proprietary Fcab™ and mAb2™ platforms. Janssen will be responsible for all research, development, and commercialization activities under the agreement.

      Neil Brewis, Ph.D., Chief Scientific Officer of F-star said, “We are pleased to collaborate with Janssen and leverage the science of F-star’s proprietary tetravalent bispecific technology. Beyond our proprietary pipeline, we believe there is broad potential for our mAb2 platform to produce multiple next-generation bispecific antibody therapeutics.”

      Under the terms of the agreement F-star is entitled to receive upfront fees of $17.5 million, near-term fees and potential further milestones of up to $1.35 billion. F-star is also eligible to receive potential tiered mid-single digit royalties on annual net sales.
      👍️0
      Phosphene Phosphene 3 years ago
      Form SC 13G F-star Therapeutics, Inc.

      https://sec.report/Document/0001104659-21-010211/

      Jasper Bos of Merck had been observer to BOD.

      👍️0
      Phosphene Phosphene 3 years ago
      F-star pipeline includes partnered programs with Merck and Denali

      Therapeutics.

      https://www.f-star.com/pipeline/proprietary-pipeline/
      👍️0

      Your Recent History

      NASDAQ
      FSTX
      F star Therapeutics
      Delayed Upgrade Clock